MarketCap
Facebook
X
Telegram
Allena Pharmaceuticals ROE Ratio | ALNA
Annual ROE Ratio Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -54.92 | -45.45 | -275.26 | -72.08 | -26.13 | 41.34 | 40.74 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.34 | -275.26 | -55.96 |
Quarterly ROE Ratio Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -382.09 | -382.09 | -430.85 | -319.28 | -267.09 | -257.62 | -253.01 | -177.08 | -198.74 | -219.33 | -227.93 | -219.89 | -178.24 | -131.63 | -95.15 | -78.07 | -58.99 | -47.62 | -25.03 | -17.79 | -14.18 | 4.37 | 8.41 | -6.84 | 10.49 | 10.35 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.49 | -430.85 | -152.11 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zai Lab Limited
ZLAB
|
-24.53 | $ 25.49 | 12.77 % | $ 27.9 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
-63.39 | $ 1.71 | 2.05 % | $ 123 M |  USA |
 |
Zoetis
ZTS
|
80.25 | $ 79.51 | -3.21 % | $ 35.3 B | USA |
 |
Global Blood Therapeutics
GBT
|
-154.32 | - | - | $ 4.62 B | USA |
 |
Inozyme Pharma
INZY
|
-176.43 | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
-197.53 | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
-348.24 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
151.25 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
3078.97 | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-68.08 | - | - | $ 59.7 M | USA |
 |
GlaxoSmithKline plc
GSK
|
39.41 | $ 50.28 | -0.27 % | $ 204 B |  Britain |
 |
Sierra Oncology
SRRA
|
-98.61 | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-139.49 | $ 1.03 | 2.95 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-57.36 | $ 4.27 | 1.18 % | $ 348 M | USA |
 |
Vaccinex
VCNX
|
748.95 | - | -61.37 % | $ 654 K | USA |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 9.9 | -0.5 % | $ 89.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
66.3 | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Jounce Therapeutics
JNCE
|
-27.81 | - | - | $ 98.4 M | USA |
 |
Immutep Limited
IMMP
|
-42.77 | $ 3.25 | 20.82 % | $ 4.73 B |  Australia |
 |
Verona Pharma plc
VRNA
|
-84.78 | - | - | $ 69.7 B | Britain |
 |
Keros Therapeutics
KROS
|
28.7 | $ 9.32 | -1.43 % | $ 347 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-169.83 | $ 7.19 | 2.71 % | $ 110 M | Australia |
 |
Corner Growth Acquisition Corp.
COOL
|
108.33 | - | -0.89 % | $ 114 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
12.23 | $ 306.2 | 2.41 % | $ 5.92 B | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-61.06 | $ 7.95 | 2.57 % | $ 535 B | Britain |
 |
Mersana Therapeutics
MRSN
|
727.65 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
21.38 | $ 53.62 | 1.67 % | $ 3.47 B |  Danmark |
 |
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-370.23 | - | - | $ 717 K | USA |
 |
Ionis Pharmaceuticals
IONS
|
-77.98 | $ 39.67 | 2.24 % | $ 6.35 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
-55.97 | $ 8.1 | 4.59 % | $ 2.89 M | USA |
 |
Immuron Limited
IMRN
|
-64.64 | $ 0.82 | -3.68 % | $ 189 M | Australia |
 |
G1 Therapeutics
GTHX
|
-135.55 | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
0.28 | - | - | $ 621 M | Britain |
 |
MediWound Ltd.
MDWD
|
-126.46 | $ 14.18 | 6.38 % | $ 386 M |  Israel |
 |
Kinnate Biopharma
KNTE
|
-70.7 | - | - | $ 123 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-64.24 | - | - | $ 7.29 B | USA |
 |
Nektar Therapeutics
NKTR
|
-182.65 | $ 37.25 | 3.04 % | $ 628 M | USA |
 |
Immunome
IMNM
|
-33.48 | $ 18.71 | 4.5 % | $ 1.63 B | USA |
 |
NexImmune
NEXI
|
-921.57 | - | 70.13 % | $ 4.12 M | USA |
 |
Kala Pharmaceuticals
KALA
|
-385.65 | $ 0.16 | 2.1 % | $ 1.3 M | USA |
 |
Theravance Biopharma
TBPH
|
35.69 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Karuna Therapeutics
KRTX
|
-34.58 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-72.64 | - | - | $ 756 M | USA |